The correlation between type 2 diabetes therapies and reduced risk of age-related diseases is evident in studies showing benefits of SGLT2 inhibitors. Similar to weight loss drugs, these therapies highlight the harmful effects of uncontrolled diabetic metabolism and excess weight. While these findings may not directly apply to thin, physically fit individuals, they shed light on the significance of managing diabetes-related metabolic processes for overall health and longevity.
A recent retrospective study in South Korea focused on individuals with type 2 diabetes taking SGLT2 inhibitors compared to other oral diabetes medications. The results showed a significantly lower incidence of Alzheimer’s disease, vascular dementia, and Parkinson’s disease in the SGLT2 inhibitor group. Adjusted for various factors, the use of SGLT2 inhibitors was associated with a notable reduction in the risk of these age-related diseases.
